Stock LIANY LIANBIO
Add to a list
To use this feature you must be a member
Log inSign up

Financials LianBio

Equities

LIANY

US53000N1081

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 20:59:59 10/05/2024 BST 		5-day change 1st Jan Change
0.32 USD +6.24% Intraday chart for LianBio +4.23% -92.84%
05-10 China's Zeekr prices US IPO at top of range to raise $441 million RE
05-07 Geely's EV Unit Zeekr Targets Up to $367.5 Million From NYSE IPO MT

Valuation

Fiscal Period: December 2021 2022
Capitalization 1 660.6 177.7
Enterprise Value (EV) 1 282.2 -120.3
P/E ratio -1.08 x -1.6 x
Yield - -
Capitalization / Revenue - -
EV / Revenue - -
EV / EBITDA -1,446,726 x 967,645 x
EV / FCF -2,829,938 x 2,601,502 x
FCF Yield -0% 0%
Price to Book 1.87 x 0.68 x
Nbr of stocks (in thousands) 107,239 108,354
Reference price 2 6.160 1.640
Announcement Date 31/03/22 28/03/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022
Net sales - - - -
EBITDA - -134.8 -195 -124.3
EBIT 1 -24.34 -134.9 -195.6 -125.4
Operating Margin - - - -
Earnings before Tax (EBT) 1 -24.33 -139.6 -195.8 -110.6
Net income 1 -24.33 -139.6 -196.3 -110.3
Net margin - - - -
EPS 2 -11.98 -11.58 -5.707 -1.022
Free Cash Flow - -102.8 -99.71 -46.25
FCF margin - - - -
FCF Conversion (EBITDA) - - - -
FCF Conversion (Net income) - - - -
Dividend per Share - - - -
Announcement Date 09/08/21 09/08/21 31/03/22 28/03/23
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3
Net sales 1 - - - - - - - - -
EBITDA 1 -13.27 -21.79 -28.15 -43 -23.45 -28.93 -25.64 -24.71 -25.98
EBIT 1 -13.54 -22.04 -60.5 -43.14 -24.55 -29.24 -25.97 -25.04 -26.3
Operating Margin - - - - - - - - -
Earnings before Tax (EBT) 1 -13.51 -22.23 -60.59 -42.39 -21.89 -18.63 -23.61 -21.42 -23.45
Net income 1 -13.11 -21.2 -61.56 -42.39 -21.9 -18.28 -24.04 -21.62 -24.04
Net margin - - - - - - - - -
EPS 2 -0.6300 -0.2800 -3.010 -0.3900 -0.2000 -0.1700 -0.2200 -0.2000 -0.2200
Dividend per Share - - - - - - - - -
Announcement Date 09/12/21 30/03/22 12/05/22 11/08/22 10/11/22 27/03/23 11/05/23 14/08/23 13/11/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022
Net Debt 1 - - - -
Net Cash position 1 42.8 252 378 298
Leverage (Debt/EBITDA) - - - -
Free Cash Flow - -103 -99.7 -46.3
ROE (net income / shareholders' equity) - -95.7% -61.4% -32.4%
ROA (Net income/ Total Assets) - -52.2% -34.6% -21%
Assets 1 - 267.6 566.6 525.3
Book Value Per Share 2 -3.250 -6.490 3.300 2.430
Cash Flow per Share 2 8.890 12.40 2.130 0.7400
Capex - 0.89 0.95 1.85
Capex / Sales - - - -
Announcement Date 09/08/21 09/08/21 31/03/22 28/03/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
LIANBIO Stock LianBio
-92.84% 34.61M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+3.91% 109B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.87% 105B
ARGENX SE Stock argenx SE
+1.28% 22.25B
BIONTECH SE Stock BioNTech SE
-13.14% 22.09B
GENMAB A/S Stock Genmab A/S
-7.05% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.36% 17.58B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.66% 16.85B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.75% 13.76B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.70% 12.46B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. LIANY Stock
  4. Financials LianBio